Novel immunotherapeutic approaches for allergy and asthma

Autoimmunity

Volumn 43, Issue 7, 2010, Pages 493-503

  O'Mahony, Liam ^a   Akdis, Mubeccel ^a   Crameri, Reto ^a   Akdis, Cezmi A ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Allergy; Asthma; T regulatory cells

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID DERIVATIVE; DACLIZUMAB; GLUCOCORTICOID; LEUKOTRIENE ANTIBODY; LEUKOTRIENE DERIVATIVE; MEPOLIZUMAB; OMALIZUMAB; PROBIOTIC AGENT; RESLIZUMAB; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; ALLERGY; ANTIBODY PRODUCTION; ASTHMA; BACTERIAL STRAIN; CELL FUNCTION; CELL PROTECTION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY CELL; MICROFLORA; NONHUMAN; PATHOGENESIS; QUALITY OF LIFE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ASTHMA; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY;

EID: 77958010820     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.3109/08916931003674725     Document Type: Review

References (114)

1. Kay AB. Allergy and allergic diseases. N Engl J Med 2001; 344:30-37.
2. Strachan DP. Hay fever, hygiene, and household size. Br Med J 1989;299:1259-1260.
3. Romagnani S. The increased prevalence of allergy and the hygiene hypothesis: Missing immune deviation, reduced immune suppression, or both? Immunol 2004;112:352-363.
4. Akdis M, Akdis CA. Therapeutic manipulation of immune tolerance in allergic disease. Nat Rev Drug Discov 2009;8: 645-660.
5. Platts-Mills TAE, Erwin EA, Woodfolk JA, Heyman PW. Environmental factors influencing allergy and asthma. In: Crameri R, editor. Allergy and asthma in modern society: A scientific approach. Basel: Karger; 2009. p 3-15.
6. Akdis M, Simon HU, Weigl L, Kreyden O, Blaser K, Akdis CA. Skin homing (Cutaneous lymphocyte-associated antigen-positive) CD8\+ T cells respond to superantigen and contribute to eosinophilia and IgE production in atopic dermatitis. J Immunol 1999;163:466-475.
7. Abernathy-Carver KJ, Sampson HA, Picker LJ, Leung DYM. Milk-induced eczema is associated with the expansion of T cells expressing cutaneous lymphocyte antigen. J Clin Invest 1995;95:913-918.
8. Kalinski P, Hilkens CMU, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol Today 1999;20: 561-567.
9. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006;441:235-238.
10. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25\+ CD4\+ Tr cells. Blood 2005;105:1162-1169.
11. Trinchieri G. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
12. Micallef MJ, Ohtsuki T, Kohno K, Tanabe F, Ushio S, Namba M, Tanimoto T, Torigoe K, Fujii M, Ikeda M, Fukuda S, Kurimoto M. Interferon-g-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: Synergism with interleukin-12 for interferon-g production. Eur J Immunol 1996;26:1647-1651.
13. Sareneva T, Matikainen S, Kurimoto M, Julkunen I. Influenza A virus-induced IFN and IL-18 synergistically enhance IFN gene expression in human T cells. J Immunol 1998;160:6032-6038.
14. Flynn S, Toellner KM, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: The B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998;188:297-304.
15. Yamazaki S, Bonito AJ, Spisek R, Dhodapkar M, Inaba K, Steinman RM. Dendritic cells are specialized accessory cells along with TGF-for the differentiation of Foxp3\+ CD4\+ regulatory T cells from peripheral Foxp3 precursors. Blood 2007;110:4293-4302.
16. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, Cianfarani F, Odorisio T, Traidl-Hoffmann C, Behrendt H, Durham SR, Schmidt-Weber CB, Cavani A. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119(12):3573-3585, doi: 10.1172/JC140202.
17. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature 1997;388:133-134.
18. Gould HJ, Sutton BJ. IgE in allergy and asthma today. Nat Rev Immunol 2008;8:205-217.
19. Mei HE, Yoshida T, Sime W, Hiepe F, Thiele K, Manz RA, Radbruch A, Dörner T. Blood-borne human plasma cells in steady-state are derived from mucosal immune responses. Blood 2009;113:2461-2469.
20. Simon H-U, Blaser K. Inhibition of programmed eosinophil death: A key pathogenic event for eosinophilia. Immunol Today 1995;16:53-55.
21. Whittaker L, Niu N, Temann UA, Stoddard A, Flavell RA, Ray A, Homer RJ, Cohn L. Interleukin-13 mediates a fundamental pathway for airway epithelial mucus induced by CD4 T cells and interleukin-9. Am J Respir Cell Mol Biol 2002;27:593-602.
22. Basinski TM, Holzmann D, Eiwegger T, Zimmermann M, Klunker S, Meyer N, Schmid-Grendelmeier P, Jutel M, Akdis CA. Dual nature of T cell-epithelium interaction in chronic rhinosinusitis. J Allergy Clin Immunol 2009;124: 74-80.
23. Akkoc T, de Koning PJ, Rückert B, Barlan I, Akdis M, Akdis CA. Increased activation-induced cell death of high IFN-gamma-producing T(H)1 cells as a mechanism of T(H)2 predominance in atopic diseases. J Allergy Clin Immunol 2008;121:652-658.
24. Sakaguchi S, YamaguchiT, Nomura T,Ono M. Regulatory T cells and immune tolerance. Cell 2008;133:775-787.
25. Taylor A, Akdis M, Joss A, Akkoç T, Wenig R, Colonna M, Daigle I, Flory E, Blaser K, Akdis CA. IL-10 inhibits CD28 and ICOS costimulations of T cells via src homology 2 domain-containing protein tyrosine phosphatase 1. J Allergy Clin Immunol 2007;120:76-83.
26. Chatila TA. Role of regulatory T cells in human diseases. J Allergy Clin Immunol 2005;116:949-959.
27. Akdis M. Healthy immune response to allergens: Tregulatory cells and more. Curr Opin Immunol 2006;18:738-744.
28. Akdis M, Verhagen J, Taylor A, Karamloo F, Karagiannidis C, Crameri R, Thunberg S, Deniz G, Valenta R, Fiebig H, Kegel C, Disch R, Schmidt-Weber CB, Blaser K, Akdis CA. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199: 1567-1575.
29. Meiler F, Zumkehr J, Klunker S, Rückert B, Akdis CA, Akdis M. In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med 2008;205: 2887-2898.
30. Hendrikx TK, Velthuis JH, Klepper M, van Gurp E, Geel A, SchoordijkW, Baan CC, WeimarW. Monotherapy rapamycin allows an increase of CD4(\+) CD25(bright\+ ) FoxP3(\+) T cells in renal recipients. Transpl Int 2009;22:884-891.
31. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, Steinfeld S, Tindall E, Becker JC, Li T, Nuamah IF, Aranda R, Moreland LW. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271.
32. Utset TO, Auger JA, Peace D, Zivin RA, Xu D, Jolliffe L, Alegre ML, Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: A phase I/II clinical trial. J Rheumatol 2002;29:1907-1913.
33. Isaacs JD, Greer S, Sharma S, Symmons D, Smith M, Johnston J, Waldmann H, Hale G, Hazleman BL. Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 2001;44:1998-2008.
34. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, Isenberg DA, Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285.
35. O'Connor RA, Anderton SM. Multi-faceted control of autoaggression: Foxp3\+ regulatory T cells in murine models of organ-specific autoimmune disease. Cell Immunol 2008; 251:8-18.
36. Roncarolo MG, Battaglia M. Regulatory T-cell immunother-apy for tolerance to self antigens and alloantigens in humans. Nat Rev Immunol 2007;7:585-598.
37. Peek EJ, Richards DF, Faith A, Lavender P, Lee TH, Corrigan CJ, Hawrylowicz CM. Interleukin-10-secreting 'regulatory' T cells induced by glucocorticoids and beta2-agonists. Am J Respir Cell Mol Biol 2005;33:105-111.
38. Karagiannidis C, Akdis M, Holopainen P, Woolley NJ, Hense G, Rückert B, Mantel PY, Menz G, Akdis CA, Blaser K, Schmidt-Weber CB. Glucocorticoids upregulate FOXP3 expression and regulatory T cells in asthma. J Allergy Clin Immunol 2004;114:1425-1433.
39. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119: 780-791.
40. Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M, Rückert B, Meiler F, Akdis M, Littman DR, Akdis CA. Transcription factors RUNX1 and RUNX3 in the induction and suppressive function of Foxp3\+ inducible regulatory T cells. J Exp Med 2009;206:2701-2715.
41. Mantel PY, Kuipers H, Boyman O, Rhyner C, Ouaked N, Rückert B, Karagiannidis C, Lambrecht BN, Hendriks RW, Crameri R, Akdis CA, Blaser K, Schmidt-Weber CB. GATA3-driven Th2 responses inhibit TGF-beta1-induced FOXP3 expression and the formation of regulatory T cells. PLoS Biol 2007;5:e329.
42. Ashbee HR, Evans EGV. Immunology of diseases associated with Malassezia species. Clin Microbiol Rev 2002;15:21-57.
43. Tengvall Linder M, Johansson C, Bengtsson A, Holm L, Harfast B, Scheynius A. Pityrosporum orbiculare-reactive T-cell lines in atopic dermatitis patients and healthy individuals. Scand J Immunol 1998;47:152-158.
44. Buentke E, Zargari A, Heffler LC, Avila-Carino J, Savolainen J, Scheynius A. Uptake of the yeast Malassezia furfur and its allergenic components by human immature CD1a\+ dendritic cells. Clin Exp Allergy 2000;30: 1759-1770.
45. Yamasaki S, Matsumoto M, Takeuchi O, Matsuzawa T, Ishikawa E, Sakuma M, Tateno H, Uno J, Hirabayashi J, Mikami Y, Takeda K, Akira S, Saito T. C-type lectin mincle is an activating receptor for pathogenic fungus, Malassezia. Proc Natl Acad Sci USA 2009;106:1897-1902.
46. Buentke E,Heffler LC,Wallin RP,Lofman C,Ljunggren HG, Scheynius A. The allergenic yeast Malassezia furfur induces maturation of human dendritic cells. Clin Exp Allergy. 2001, 31, 1583-1593.
47. Gabrielsson S, Buentke E, Lieden A, Schmidt M, D'Amato M, Tengvall Linder M, Scheynius A. Malassezia sympodialis stimulation differently affects gene expression in dendritic cells from atopic dermatitis patients and healthy individuals. Acta Dermatol Venereol 2004;84:339-345.
48. Agerberth B, Buentke E, Bergman P, Eshaghi H, Gabrielsson S, Gudmundsson GH, Scheynius A. Malassezia sympodialis differently affects the expression of LL-37 in dendritic cells from atopic eczema patients and healthy individuals. Allergy 2006;61:422-430.
49. O'Driscoll RB, Hopkinson L, Denning DW. Mold sensitis-ation allergy is common amongst patients with severe asthma requiring multiple hospital admissions. BMC Pulm Med 2005;5:4.
50. Slavin RG, Hutcheson PS, Chauhan B, Bellone CJ. An overview of allergic bronchopulmonary aspergillosis with some new insights. Allergy Asthma Proc 2004;25:395-399.
51. Vande Veerdonk FL, Kullberg BJ, van der Meer JW, Gow NA, Netea MG. Host-microbe interactions: Innate pattern recognition of fungal pathogens. Curr Opin Microbiol 2008;11:305-312.
52. Bellocchio S, Montagnoli C, Bozza S, Gaziano R, Rossi G, Mambula SS, Vecchi A, Mantovani A, Levitz SM, Romani L. The contribution of Toll-like/IL-1 receptor superfamily to innate and adaptive immunity to fungal pathogens in vivo. J Immunol 2004;172:3059-3069.
53. Glaser AG, Menz G, Kirsch AI, Zeller S, Crameri R, Rhyner C. Auto-and cross-reactivity to thioredoxin allergens in allergic bronchopulmonary aspergillosis. Allergy 2008;63: 1617-1623.
54. Breuer K, Kapp A, Werfel T. Bacterial infections and atopic dermatitis. Allergy 2001;56:1034-1041.
55. Shiomori T, Yoshida S, Miyamoto H, Makishima K. Relationship of nasal carriage of Staphylococcus aureus to pathogenesis of perennial allergic rhinitis. J Allergy Clin Immunol 2000;105:449-454.
56. Bachert C, Gevaert P, Howarth P, Holtappels G, van Cauwenberge P, Johansson SG. IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthma. J Allergy Clin Immunol 2003;111:1131-1132.
57. Lee JH, Lin YT, Yang YH, Wang LC, Chiang BL. Increased levels of serum-specific immunoglobulin E to staphylococcal enterotoxin A and B in patients with allergic rhinitis and bronchial asthma. Int Arch Allergy Immunol 2005;138: 305-311.
58. Semic-Jusufagic A, Bachert C, Gevaert P, Holtappels G, Lowe L, Woodcock A, Simpson A, Custovic A. Staphylococcus aureus sensitization and allergic disease in early childhood: Population-based birth cohort study. J Allergy Clin Immunol 2007;119:930-936.
59. Laouini D, Kawamoto S, Yalcindag A, Bryce P, Mizoguchi E, Oettgen H, Geha RS. Epicutaneous sensitization with superantigen induces allergic skin inflammation. J Allergy Clin Immunol 2003;112:981-987.
60. Mandron M, Ariès MF, Brehm RD, Tranter HS, Acharya KR, Charveron M, Davrinche C. Human dendritic cells conditioned with Staphylococcus aureus enterotoxin B promote TH2 cell polarization. J Allergy Clin Immunol 2006;117:1141-1147.
61. Liu T, He SH, Zheng PY, Zhang TY, Wang BQ, Yang PC. Staphylococcal enterotoxin B increases TIM4 expression in human dendritic cells that drives näve CD4 T cells to differentiate into Th2 cells. Mol Immunol 2007;44: 3580-3587.
62. Lai Y, Di Nardo A, Nakatsuji T, Leichtle A, Yang Y, Cogen AL, Wu ZR, Hooper LV, Schmidt RR, von Aulock S, Radek KA, Huang CM, Ryan AF, Gallo RL. Commensal bacteria regulate Toll-like receptor 3-dependent inflammation after skin injury. Nat Med 2009;15:1377-1382, doi: 10.1038/nm.2062.
63. Van der Kleij H, O'Mahony C, Shanahan F, O'Mahony L, Bienenstock J. Protective effects of Lactobacillus reuteri and Bifidobacterium infantis in murine models for colitis do not involve the vagus nerve. Am J Physiol Regul Integr Comp Physiol 2008;295:1131-1137.
64. Sheil B, McCarthy J, O'Mahony L, Bennett MW, Ryan P, Fitzgibbon JJ, Kiely B, Collins JK, Shanahan F. Is the mucosal route of administration essential for probiotic function? Subcutaneous administration is associated with attenuation of murine colitis and arthritis. Gut 2004;53: 694-700.
65. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003;52:975-980.
66. O'Mahony L, Feeney M, O'Halloran S, Murphy L, Kiely B, Fitzgibbon J, Lee G, O'Sullivan G, Shanahan F, Collins JK. Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice. Aliment Pharmacol Ther 2001;15:1219-1225.
67. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 2008;453:620-625.
68. Grabig A, Paclik D, Guzy C, Dankof A, Baumgart DC, Erckenbrecht J, Raupach B, Sonnenborn U, Eckert J, Schumann RR, Wiedenmann B, Dignass AU, Sturm A. Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2-and toll-like receptor 4-dependent pathways. Infect Immun 2006;74:4075-4082.
69. Di Giacinto C, Marinaro M, Sanchez M, Strober W, Boirivant M. Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-b bearing regulatory cells. J Immunol 2005;174:3237-3246.
70. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O'Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kB activation. PLOS Pathogens 2008;4:e1000112.
71. Karimi K, Inman MD, Bienenstock J, Forsythe P. Lactoba-cillus reuteri-induced regulatory T cells protect against an allergic airway response in mice. Am J Respir Crit Care Med 2009;179:186-193.
72. Karim M, Kingsley CI, Bushell AR, Sawitzki BS, Wood KJ. Alloantigen-induced CD25\+ CD4\+ regulatory T cells can develop in vivo from CD25-CD4\+ precursors in a thymus-independent process. J Immunol 2004;172:923-928.
73. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4\+ CD25-naive T cells to CD4\+ CD25\+ regulatory T cells by TGF-b induction of transcription factor Foxp3. J Exp Med 2003;198:1875-1886.
74. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, Powrie F. A functionally specialized population of mucosal CD103\+ DCs induces Foxp3\+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007;204:1757-1764.
75. Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007;204:1775-1785.
76. Lyons A, O'Mahony D, O'Brien F, MacSharry J, Sheil B, Ceddia M, Russell WM, Forsythe P, Bienenstock J, Kiely B, Shanahan F, O'Mahony L. Bacterial strain-specific induction of Foxp3\+ T regulatory cells is protective in murine allergy models. Clin Exp Allergy; 2010 Jan 11 [Epub ahead of print].
77. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell 2005;122: 107-118.
78. Betsi GI, Papadavid E, Falagas ME. Probiotics for the treatment or prevention of atopic dermatitis: A review of the evidence from randomized controlled trials. Am J Clin Dermatol 2008;9:93-103.
79. Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: A double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol; 2009 Oct 14 [Epub ahead of print].
80. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev 2008;8:CD006135.
81. SennaG, RidoloE,CalderonM,Lombardi C,CanonicaGW, Passalacqua G. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9: 544-548.
82. ThomasWR. Innovationinimmunotherapy.Clin Exp Allergy 2009;39:450-454.
83. Crameri R. Allergy vaccines: Dreams and reality. Exp Rev Vaccines 2007;6:991-999.
84. Rezvani M, Bernstein DI. Anaphylactic reactions during immunotherapy. Immunol Allergy Clin North Am II 2007; 27:295-307.
85. Maasch HJ, Marsh DG. Standardized extracts modified allergens-allergoids. Clin Rev Allergy 1987;5:89-106.
86. Crameri R, Rhyner C. Novel vaccines and adjuvants for allergen-specific immunotherapy. Curr Opin Immunol 2006; 18:761-768.
87. Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007;119: 906-909.
88. Williams A, Henzgen M, Rajakulasingam K. Additional benefit of a third year of specific grass pollen allergoid immunotherapy in patients with seasonal allergic rhinitis. Eur Ann Allergy Clin Immunol 2007;39:123-126.
89. Müller U, Akdis CA, Fricker M, Akdis M, Blesken T, Bettens F, Blaser K. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998;101:747-754.
90. Alexander C, Tarzi M, Larché M, Kay AB. The effect of Feld 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy 2005;60: 1269-1274.
91. Kussebi F, Karamloo F, Rhyner C, Schmid-Grendelmeier P, Salagianni M, Mannhart C, Akdis M, Soldatova L, Markovic-Housley Z, Von Beust BR, Kündig T, Kemeny DM, Blaser K, Crameri R, Akdis CA. A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy. J Allergy Clin Immunol 2005;115: 323-329.
92. Walgraffe D, Mattéotti C, El Bakkoury M, Garcia L, Marchand C, Bullens D, Vandenbranden M, Jacquet A. A hypoallergenic variant of Der p 1 as a candidate for mite allergy vaccines. J Allergy Clin Immunol. 2009;123: 1150-1156.
93. Purohit A, Niederberger V, Kronqvist M, Horak F, Grönneberg R, Suck R, Weber B, Fiebig H, van Hage M, Pauli G, Valenta R, Cromwell O. Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 2008;38: 1514-1525.
94. Durham SR. Sublingual immunotherapy: What have we learnt from the 'big trials'? Curr Opin Allergy Clin Immunol 2008;8:577-584.
95. Pajano GB. Sublingual immunotherapy: The optimism and the issue. J Allergy Clin Immunol 2007;119:796-801.
96. Kündig TM, Senti G, Schnetzler G, Wolf C, Prinz Vavricka BM, Fulurija A, Hennecke F, Sladko K, Jennings GT, Bachmann MF. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006;117:1470-1476.
97. Senti G, Johansen P, Haug S, Bull C, Gottschaller C, Müller P, Pfister T, Maurer P, Bachmann MF, Graf N, Kündig TM. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: A phase I/IIA clinical trial. Clin Exp Allergy 2009;39:562-570.
98. Senti G, Prinz Vavricka BM, Erdmann I, Diaz MI, Markus R, McCormack SJ, Simard JJ, Wüthrich B, Crameri R, Graf N, Johansen P, Kündig TM. Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial. Proc Natl Acad Sci USA 2008; 105:17908-17912.
99. Crameri R, Kündig TM, Akdis CA. Modular antigen-translocation as a novel vaccine strategy for allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9: 568-573.
100. Senti G, Johansen P, Kündig TM. Intralymphatic immu-notherapy. Curr Opin Allergy Clin Immunol 2009;9: 537-543.
101. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008;121: 288-296.
102. Busse WW, Israel E, Nelson HS, Baker JW, Charous BL, Young DY, Vexler V, Shames RS. Daclizumab Asthma Study Group. Daclizumab improves asthma control in patients with moderate to severe persistent asthma: A randomized, controlled trial. Am J Respir Crit Care Med 2008;178: 1002-1008.
103. Flood-Page PT, Manzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167:199-204.
104. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, Danzig M, Cuss F, Pauwels RA. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: A pilot study. Am J Respir Crit Care Med 2003;167:1655-1659.
105. Flood-Page P, Menzies-Gow A, Phipps S, Ying S, Wangoo A, Ludwig MS, Barnes N, Robinson D, Kay AB. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112:1029-1036.
106. Andrews AL, Holloway JW, Holgate ST, Davies DE. IL-4 receptor alpha is an important modulator of IL-4 and IL-13 receptor binding: Implications for the development of therapeutic targets. J Immunol 2006;176:7456-7461.
107. Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebocontrolled trial. Am J Respir Crit Care Med 1999;160:1816-1823.
108. Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, Agosti JM. IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001;107: 963-970.
109. Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: A double blind, randomised, placebo controlled trial. Thorax 2008;63:584-591.
110. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, Bradding P, Brightling CE, Wardlaw AJ, Pavord ID. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354: 697-708.
111. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlén SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J, Horvath I, Mark Z, Bernstein D, Kerwin E, Schlenker-Herceg R, Lo KH, Watt R, Barnathan ES, Chanez P. T03 Asthma Investigators. A randomized, double-blind, placebo-controlled study of TNF-{alpha} blockade in severe persistent asthma. Am J Respir Crit Care Med 2009;179:549-558.
112. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W, Von Berg A, Leupold W, Bergmann KC, Rolinck-Wernin-ghaus C, Gräve M, Hultsch T, Wahn U. Efficacy of combination treatment with anti-IgE plus specific immu-notherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002;109: 274-280.
113. Casale TB, Busse WW, Kline JN, Ballas ZK, Moss MH, Townley RG, Mokhtarani M, Seyfert-Margolis V, Asare A, Bateman K, Deniz Y. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006;117:134-140.
114. Engelhardt H, Smits RA, Leurs R, Haaksma E, de Esch IJ. A new generation of anti-histamines: Histamine H4 receptor antagonists on their way to the clinic. Curr Opin Drug Discov Devel 2009;12:628-643.